Hao Zhu1, Sonia Napravnik, Joseph J Eron, Stephen R Cole, Ye Ma, David A Wohl, Zhihui Dou, Yao Zhang, Zhongfu Liu, Decai Zhao, Lan Yu, Xia Liu, Myron S Cohen, Fujie Zhang. 1. *Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC; †Division of Treatment and Care, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; ‡Division of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC; and §Division of Infectious Diseases, Beijing Ditan Hospital Capital Medical University, Beijing, China.
Abstract
OBJECTIVE: To evaluate excess mortality across calendar time comparing HIV-infected patients receiving combination antiretroviral therapy (cART) with the general Chinese population. METHODS: Patients receiving free cART through the National Free Antiretroviral Therapy Program (NFATP) between January 1, 2003, and December 31, 2009, were included. Observed mortality rates, excess mortality rates, and standardized mortality ratios were calculated by calendar periods. Factors associated with excess mortality across calendar time were evaluated in multivariable Poisson regression models. RESULTS: Among 64,836 HIV-infected patients, the observed and excess mortality rates in 2003-2004 were 9.5 deaths per 100 person-years [95% confidence interval (CI): 8.8 to 10.2] and 9.1 (95% CI: 8.5 to 9.8); in 2008-2009, these decreased to 5.6 (95% CI: 5.4 to 5.8) and 5.2 (95% CI: 5.0 to 5.4), respectively. The adjusted excess hazard ratio (eHR) for 2003-2004 in comparison to 2008-2009 was 1.27 (95% CI: 1.11 to 1.45). Patients initiating cART at CD4 cell counts <50 cells per microliter in comparison with ≥350 cells per microliter had an adjusted eHR of 9.92 (95% CI: 8.59 to 11.44). Patients starting cART at older ages also had greater excess mortality with an eHR of 1.63 (95% CI: 1.47 to 1.82) comparing ages ≥45 to 18-29 years. Standardized mortality ratio results were consistent with those for excess mortality. CONCLUSIONS: Substantial decreases in excess mortality were observed from 2003 to 2009 in China among HIV-infected patients receiving free cART. However, mortality among HIV-infected patients remained higher than the general Chinese population. As more efficacious first- and second-line cART regimens become increasingly available to Chinese HIV-infected patients, further reductions in overall and excess mortality are likely.
OBJECTIVE: To evaluate excess mortality across calendar time comparing HIV-infectedpatients receiving combination antiretroviral therapy (cART) with the general Chinese population. METHODS:Patients receiving free cART through the National Free Antiretroviral Therapy Program (NFATP) between January 1, 2003, and December 31, 2009, were included. Observed mortality rates, excess mortality rates, and standardized mortality ratios were calculated by calendar periods. Factors associated with excess mortality across calendar time were evaluated in multivariable Poisson regression models. RESULTS: Among 64,836 HIV-infectedpatients, the observed and excess mortality rates in 2003-2004 were 9.5 deaths per 100 person-years [95% confidence interval (CI): 8.8 to 10.2] and 9.1 (95% CI: 8.5 to 9.8); in 2008-2009, these decreased to 5.6 (95% CI: 5.4 to 5.8) and 5.2 (95% CI: 5.0 to 5.4), respectively. The adjusted excess hazard ratio (eHR) for 2003-2004 in comparison to 2008-2009 was 1.27 (95% CI: 1.11 to 1.45). Patients initiating cART at CD4 cell counts <50 cells per microliter in comparison with ≥350 cells per microliter had an adjusted eHR of 9.92 (95% CI: 8.59 to 11.44). Patients starting cART at older ages also had greater excess mortality with an eHR of 1.63 (95% CI: 1.47 to 1.82) comparing ages ≥45 to 18-29 years. Standardized mortality ratio results were consistent with those for excess mortality. CONCLUSIONS: Substantial decreases in excess mortality were observed from 2003 to 2009 in China among HIV-infectedpatients receiving free cART. However, mortality among HIV-infectedpatients remained higher than the general Chinese population. As more efficacious first- and second-line cART regimens become increasingly available to Chinese HIV-infectedpatients, further reductions in overall and excess mortality are likely.
Authors: Lauren E Cain; James M Robins; Emilie Lanoy; Roger Logan; Dominique Costagliola; Miguel A Hernán Journal: Int J Biostat Date: 2010 Impact factor: 0.968
Authors: Christian Jaggy; Jan von Overbeck; Bruno Ledergerber; Claude Schwarz; Matthias Egger; Martin Rickenbach; Hans-Jakob Furrer; Amalio Telenti; Manuel Battegay; Markus Flepp; Pietro Vernazza; Enos Bernasconi; Bernard Hirschel Journal: Lancet Date: 2003-09-13 Impact factor: 79.321
Authors: Søren Jensen-Fangel; Lars Pedersen; Court Pedersen; Carsten S Larsen; Palle Tauris; Axel Møller; Henrik T Sørensen; Niels Obel Journal: AIDS Date: 2004-01-02 Impact factor: 4.177
Authors: Margaret T May; Jonathan A C Sterne; Dominique Costagliola; Caroline A Sabin; Andrew N Phillips; Amy C Justice; François Dabis; John Gill; Jens Lundgren; Robert S Hogg; Frank de Wolf; Gerd Fätkenheuer; Schlomo Staszewski; Antonella d'Arminio Monforte; Matthias Egger Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Paula Braitstein; Martin W G Brinkhof; François Dabis; Mauro Schechter; Andrew Boulle; Paolo Miotti; Robin Wood; Christian Laurent; Eduardo Sprinz; Catherine Seyler; David R Bangsberg; Eric Balestre; Jonathan A C Sterne; Margaret May; Matthias Egger Journal: Lancet Date: 2006-03-11 Impact factor: 79.321
Authors: Kevin P Fiori; Hayley M Belli; Molly E Lauria; Lisa R Hirschhorn; Jennifer Schechter; Emily Hansman; Nandita Rajshekhar; Venance Katin; Sesso Gbeleou; Meskerem Grunitsky-Bekele; Vincent Palokinam Pitche Journal: AIDS Care Date: 2019-06-06
Authors: Kaku A So-Armah; Janet P Tate; Chung-Chou H Chang; Adeel A Butt; Mariana Gerschenson; Cynthia L Gibert; David Leaf; David Rimland; Maria C Rodriguez-Barradas; Matthew J Budoff; Jeffrey H Samet; Lewis H Kuller; Steven G Deeks; Kristina Crothers; Russell P Tracy; Heidi M Crane; Mohammad M Sajadi; Hilary A Tindle; Amy C Justice; Matthew S Freiberg Journal: J Acquir Immune Defic Syndr Date: 2016-06-01 Impact factor: 3.731
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546